In AL Amyloidosis Treated with Bortezomib, t(11;14) Associated with Adverse Outcomes

Share this content:
Newly diagnosed patients with AL amyloidosis who harbor t(11;14) see less treatment benefit with bortezomib.
Newly diagnosed patients with AL amyloidosis who harbor t(11;14) see less treatment benefit with bortezomib.

Newly diagnosed patients with AL amyloidosis who harbor t(11;14) see less treatment benefit with bortezomib, according to a recent study published in the Journal of Clinical Oncology.

Researchers led by Tilmann Bochtler, MD, of the University Hospital Heidelberg in Germany examined 101 patients with AL amyloidosis who were treated with bortezomib-dexamethasone as first-line treatment through interphase fluorescence in situ hybridization (iFISH).

“Bortezomib has become a cornerstone in the treatment of AL amyloidosis,” the authors noted. “We addressed the prognostic impact of cytogenetic aberrations for bortezomib-treated patients.”

They found that there was inferior hematologic event-free survival, overall survival, and remission rate in patients who had t(11;14) compared to those who didn't.

RELATED: Diagnosis and Management of Castleman Disease

In multivariable Cox regression models, t(11;14) was found to be an independent adverse prognostic marker for hematologic event-free and overall survival, but not remission.

“iFISH results are important independent prognostic factors in AL amyloidosis,” the authors concluded.

Reference

  1. Bochtler, Tilmann, et al. "Translocation t(11;14) Is Associated With Adverse Outcome in Patients With Newly Diagnosed AL Amyloidosis When Treated With Bortezomib-Based Regimens." Journal of Clinical Oncology. doi: 10.1200/JCO.2014.57.4947. [epub ahead of print]. March 16, 2015.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters